Doxorubicin is known to be active against a range of solid tumours and is one of the best available agents in the treatment of breast cancer (Bonadonna et al., 1970; O'Bryan et al., 1973; Blum & Carter, 1974) . However, both inherent and acquired resistance are in many cases major obstacles in successful treatment (O'Bryan et al., 1977) . Increased levels of expression of the mdrl gene, which codes for a 175 kDa plasma membrane associated glycoprotein, and the gst-rc gene, encoding the anionic isozyme of glutathione Stransferase (GSTh) have previously been shown in doxorubicin (adriamycin) resistant cell lines, derived by drug selection in culture Riordan et al., 1985; Scotto et al., 1986; Cowan et al., 1986; Deffie et al., 1988; Van der Bliek et al., 1988) . Many of these cell lines have been shown to be cross resistant to other chemotherapeutic agents such as Vinca alkaloids, anthracyclines and epipodophyllotoxins and have been termed multidrug resistant (MDR). The 175 kDa plasma membrane-associated protein, Pglycoprotein, has been suggested to increase resistance to a variety of drugs by increasing their efflux from the cell (Gerlach et al., 1986; Chen et al., 1986) . GST isozymes have in common the ability to catalyse conjugation of drugs to reduced glutathione leading to drug detoxification (Jakoby, 1978) .
A range of expression of mdr and gst-it has been shown in human tumour samples, both between tumours derived from different tissues and derived from the same tissue (Goldstein et al., 1989; Gerlach et al., 1987; Moscow et al., 1989) . However, the relationship between levels of expression of mdrl or gst-rc and clinical drug resistance has yet to be fully elucidated. The identification of particular mechanisms of resistance in a tumour type is important for treatments designed to circumvent resistance (Kaye, 1988) . In this present study we have measured RNA levels of mdri and gst-ir in untreated human breast tumour biopsies. We have compared the expression of these genes in breast cancer with other tumour types including colon tumours, head and neck squamous cell carcinomas and leukaemias, as well as cell lines selected for resistance to doxorubicin. We have also analysed epithelial cells grown during short term culture of breast tumour biopsies for in vitro sensitivity to doxorubicin, as measured by a colony forming assay (Smith et al., 1981a,b 
Materials and methods
RNA extraction from tumour biopsies Tumour biopsies were frozen in liquid nitrogen immediately after surgical removal and were stored frozen at -70°C. All solid tumour samples were from patients who had not received any chemotherapy. Routine histology of the samples confirmed that the majority of the biopsy consisted of tumour cells. Solid tumours were pulverised whilst still frozen in a micro-dismembrator II (Braun, FRG) and DNA and RNA extracted by cell lysis and phenol/chloroform extraction (Kreig et al., 1983) . Nucleated cells were isolated from the leukaemic samples by ficoll gradient centrifugation and RNA/DNA isolated as described above. DNA was removed from the samples by digestion with RNase-free DNase I (BCL, molecular biology grade). The quantity and quality of the RNA was initially assessed by the presence of ribosomal 28S and 18S RNA after electrophoresis in agarose.
Hybridisation probes An mdrl probe, mdr5A, which encodes about one-third of the coding region of a full-length mdrl cDNA has previously been described . One tLg of BamHl digested mdr5A was used as substrate for a riboprobe transcription kit (BCL) in the presence of uridine 5' a-32P-triphosphate (30 TBq mmol-') from Amersham and SP6 polymerase. A full-length cDNA of gst-in, pGPi (Kano et al., 1987) , was cloned into the EcoRI site of the polylinker of the riboprobe vector Bluescribe (Pharmacia). One fg of HindIII digested pGPi probe was used as substrate for riboprobe transcription as described above. The 7S probe (Balmain et al., 1982) Hybridisation analysis Northern hybridisation The RNA was electrophoresed in 1.4% agarose/6% formaldehyde gels and transferred to Gene Screen membranes (NEN/DuPont). Hybridisation was in 50% formamide buffer as previously described (Shen et al., 1986) for 16 h at 57°C with 5 x 106 c.p.m. of synthetic RNA per ml. The filters were washed with 2 x SSC/0.1% SDS for 15 min at room temperature followed by two 20 min washes at 65°C with 0.1 x SSC/0. 1% SDS. Autoradiograms were exposed for 1-3 days. Amounts of RNA on the filters were quantified by reprobing the same filter with a probe for 7S RNA and intensity of signal measured by densitometrical scanning.
Dot blot hybridisation Gene screen filters were presoaked in 0.25 M di-sodium phosphate buffer and 15, 5, 1.6 and 0.5 lag of total RNA applied. After baking, prehybridisation, hybridisation and washing were performed exactly as described above for the Northern hybridisation experiments. Amounts of RNA on the filters were quantified by reprobing the same filter with a kinase labelled poly d(T) oligomer as previously described (Harley, 1987) . Repeat identical RNA from tumours, MDR cell lines and their parental drug sensitive cell lines which had a range of both mdrl and gstn expression were analysed on all filters to allow comparison between experiments. Autoradiograms were exposed overnight and intensity of signals were quantified using densitometrical scanning.
Colony forming assay for doxorubicin sensitivity of breast tumour outgrowths Sensitivity of breast cells to doxorubicin was assessed using the short-term colony forming assay described by Smith et al. (1981b Smith et al. ( , 1985 . Tumour tissue was minced and disaggregated in medium containing 200 U pl`c ollagenase (Worthington).
Resultant ductal alveolar structures and clumps of cells were plated onto plastic and allowed to grow for 7-10 days. Growth was supported in nutrient medium F10/DMEM supplemented with 10-9 M oestradiol, 10 jg ml-' insulin, 5 fig ml-' transferin and 5 mg ml-' epidermal growth factor.
Outgrowth cells were then trypsinised, counted and plated onto mitomycin C (4 mg ml-') treated STO mouse fibroblast feeder layers. They were then exposed to a range of eight concentrations of doxorubicin (from 5 x 10-6 M to 3.4 x 10-M) for 24 h. Drug was removed, the nutrient medium replaced and surviving colonies counted after 2 weeks. Sensitivity was determined by the amount of drug required to kill 50% of the control untreated cells (ID50). Greater detail of this assay and analysis of a large number of breast tumours will be published separately (S. Stallard, in preparation).
Results mdrl mRNA levels in human tumours RNA prepared from human tumours and cell lines were analysed by dot-blot hybridisation using the same conditions of stringency that detect specific 4.5 kb mdrl mRNA transcripts and 0.7 kb gst-i transcripts in Northern hybridisations. Typical dot-blots and Northern hybridisations using each probe are shown in Figure 1 . Of 49 primary breast tumour biopsies from untreated patients, 25 samples had measurable levels of mdrl mRNA (Figure 2 ). High levels of mdrl mRNA were also detected in one breast tumour lymph node biopsy. The levels of mdrl mRNA in some of these tumours reached levels equivalent to that detected in cell lines selected for drug resistance in vitro. Signal intensity of20 fig
RNA from the cell lines MCF-7ADR (Cowan et al., 1986) , A2780AD (Rogan et al., 1984) and H69LX1O ( tumour samples. Of fourteen untreated squamous cell carcinomas of the head and neck, eight had measurable levels of mdrl mRNA. Detectable mdrl mRNA was also present in three out of five untreated acute myeloid leukaemia (AML) samples. The chronic myeloid leukaemia (CML) samples shown represent sequential samples from the same patient. The sample with undetectable mdrl RNA was taken prior to chemotherapy, while the sample with detectable expression was taken after anthracycline based chemotherapy.
gst-ic mRNA levels in human tumours Figure 3 shows the gst- ¶c mRNA levels detected in the same tumour samples as shown in Figure 2 . Signal intensity of 20 Lg RNA from the cell lines MCF-7ADR (Cowan et al., 1986) , A2087AD (Rogan et al., 1984) and H69LX1O (an adriamycin resistant cell line isolated from a human lung cell line; P. Twentyman, personal communication) had values of 60, 55 and 10 respectively. Dot blot hybridisations contained RNAs from the adriamycin resistant cell line, H69LXIO and the parental drug sensitive line, H69, as well as repeat samples of the tumour RNAs to allow comparison between hybridisation experiments as described in the Materials and methods. Undetectable and very low signal intensities were given an arbitrary value of 1. All the breast tumour samples, with the exception of one, showed low or undetectable levels of gst-ic mRNA. On the other hand all of the colon tumours, with the exception of one, showed relatively high levels of transcripts. The leukaemia samples generally had low levels of gst-i, including the sequential CML samples taken during chemotherapy. A large proportion of squamous cell carcinomas of the head and neck had high levels of gst- ¶c mRNA levels. mdrl and gst-i may be occurring, as has been observed for adriamycin resistant MCF7 breast cell lines (Cowan et al., 1986) .
Comparison of mdrl and gst-7 mRNA levels to in vitro sensitivity of cell outgrowths of breast tumours
Comparison of doxorubicin IDm to mdrl and gst-7c mRNA level is shown in Figure 4 Figure 4 to allow comparison between mdrl and gst-ic expression. Sample number 13 showed high levels of mdrl and gst-1 expression. Comparison between mdrl and gst-7 mRNA levels in all the breast samples assayed shows a low level of correlation which is only slightly significant (r = 0.48, P <0.1). Thus for some of these tumours coexpression of Discussion Doxorubicin is widely used in the treatment of advanced breast cancer, with an overall response rate among breat cancer patients of about 55% (Blum & Carter, 1974; O'Bryan et al., 1977) . This means that almost half the patients are resistant to doxorubicin from the outset of treatment. A better understanding of the mechanisms underlying this resistance should lead to improved therapeutic results. Drug delivery studies in breast cancer patients suggest that defective delivery of adriamycin into breast tumours is unlikely to be a major factor (Stallard et al., 1990) . Increased mdr and gst-i expression have been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin (Cowan et al., 1986; Moscow et al., 1988) . Several lines of evidence support the involvement of mdrl expression in resistance of tumours to chemotherapy: (a) full-length cDNAs for the mdrl gene transfected (Ueda et al., 1987a) or infected (Guild et al., 1988) into cells confer multidrug resistance; (b) tumour types which are clinically drug resistant, such as colon, generally have elevated mdrl mRNA levels (Goldstein et al., 1989; Fojo et al., 1987b) drug resistant phenotype which is reversible by inhibitors of the multidrug transporter such as verapamil and quinidine (Fojo et al., 1987a) ; (d) immunocytohistochemical staining for P-glycoprotein expression correlates with in vitro sensitivity to doxorubicin of tumour tissue from patients (Salmon et al., 1989) .
We have detected mdrl mRNA in 25 out of 49 primary breast tumour biopsies from untreated patients. Detectable mdrl expression has also been observed in one out of three lymph node biopsies. In these untreated tumours a hundred fold range in expression of mdrl has been observed with some samples reaching the levels observed in resistant cell lines selected in vitro. Levels of mdrl expression in about 20% of the breast tumour samples are equivalent to the levels we detect in intrinsically chemoresistant colon tumours. These results support a possible involvement of mdrl expression in response to chemotherapy of some breast tumours.
In vitro chemosensitivity to doxorubicin of epithelial cells grown from breast tumour biopsies showed that no sample which is relatively sensitive to doxorubicin was observed to have high mdrl or gst-i mRNA level. All of the samples with high mdrl levels have relatively high IDs for doxorubicin. These observations are supportive of a role for mdrl expression in limiting the response of breast cells to doxorubicin. A number of tumour samples however are relatively resistant to doxorubicin, yet have low levels of mdrl expression. In these tumours alternative resistance mechanisms may be effective.
Increased expression of gst-i, co-expressed with mdrl, has been observed in some doxorubicin resistant breast tumour cells (Cowan et al., 1986) . With one exception, we have detected low levels of gst-x mRNA in the breast tumour samples. No large differences in expression levels were detected and no significant correlation with doxorubicin sensitivity of outgrowths was observed. However, it is still possible that gst-r expression may have a role in chemoresponsiveness of a subset of breast tumours. A weak correlation exists between expression of mdrl and gst-n in the breast tumour samples we have analysed, suggesting that common mechanisms may be involved in their expression.
Our results show that mdrl expression can be detected in approximately half of the breast tumours analysed and that explants from tumours with high mdrl expression are relatively more resistant to doxorubicin in vitro. These results are in agreement with those of Salmon et al. (1989) , who recently showed that five out of 13 breast tumours stained positively with a P-glycoprotein antibody and that all five of these tumours were 'resistant' using a short-term in vitro assay of doxorubicin sensitivity. Goldstein et al. (1989) have found detectable levels of mdrl mRNA in nine of 57 untreated breast tumour biopsies. However, Merkel et al. (1989) found no mdrl mRNA in 53 untreated breast tumour samples. The differences in proportions of tumours with detectable mdrl mRNA may be due to technical variations in sensitivity of the hybridisation conditions used. The stringent hybridisation conditions used in this present study detect only the mdrl specific 4.5 kb mRNA and appropriate positive and negative control RNAs were included in hybridisation experiments. However, the differences in detection of mdrl mRNA may also represent variations in mdrl expression in tumours from different geographical locations. Exposure to carcinogens has been shown in animal model carcinogenesis systems to affect levels of mdr expression (Gottesman, 1988) . Differences in proportions of tumours with detectable mdr expression may reflect variations in tumour aetiology and carcinogen exposure in different geographical locations. We have also detected mdrl expression in squamous cell carcinomas of the head and neck and in samples from AML patients. All of these samples were from patients who had not received chemotherapy.
Direct evidence for involvement of mdrl expression in clinical response of tumours to chemotherapy would require a prospective clinical trial. Drug resistance in multidrug resistant cell lines can be overcome in vitro using agents such as verapamil and quinidine which are thought to act by competitively binding to the P-glycoprotein (Safa, 1988) . High expression of P-glycoprotein in breast tumours suggest that trials using such reversing agent in conjunction with chemotherapy may be appropriate for breast cancer. For some drugs, such as quinidine, the levels which are clinically achievable are equivalent to those which are effective in vivo and a controlled clinical trial in breast cancer using quinidine is underway in our department.
